Skip to content
Screener

BioMarin Pharmaceuticals BMRN Total Liabilities & Equity

Total Liabilities & Equity at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$3.19B-13.4%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$2.87B+8.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$302.71M+18.1%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$1.11B-24.7%
Regenxbio logo
RegenxbioRGNX
$386.62M-33.5%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$1.37B+55.5%

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
ASSETSJune 30, 2026 / (unaudited)December 31, 2025 ⁽¹⁾
Stockholders’ equity:
Common stock, $0.001 par value: 500,000,000 shares authorized; 193,535,556 and 192,300,101 shares issued and outstanding, respectively194192
Additional paid-in capital6,037,0195,956,582
Company common stock held by the Nonqualified Deferred Compensation Plan(11,233)(10,508)
Accumulated other comprehensive loss(8,783)(13,473)
Retained earnings304,495154,206
Total stockholders’ equity6,321,6926,086,999
Total liabilities and stockholders’ equity$11,723,442$7,594,022

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's total liabilities & equity?
BioMarin Pharmaceuticals (BMRN) reported total liabilities & equity of $11.72B in Q2 2026.
How has BioMarin Pharmaceuticals's total liabilities & equity changed year-over-year?
BioMarin Pharmaceuticals's total liabilities & equity increased by 57.2% year-over-year, from $7.46B to $11.72B.
What is the long-term trend for BioMarin Pharmaceuticals's total liabilities & equity?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's total liabilities & equity has grown at a 5.4% compound annual growth rate (CAGR), from $5.85B to $7.59B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about BioMarin Pharmaceuticals's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude